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1. Introduction
One of the major recent advances in medicine is the use of living cells for treatment. For
example, hematopoietic stem cells (HSCs) have been transplanted to leukemic patients (bone
marrow transplantation) (McGovern et al., 1956; Atkinson et al., 1959; Thomas et al., 1959).
Isolated stem cells from the donor were infused into the recipient’s blood stream. Those infused
cells replaced the recipient’s diseased HSCs. Similarly, pancreatic islets were isolated from
donors and transplanted to diabetic patients (Shapiro et al., 2000). In these applications, the
cells were isolated and used directly without modifications. From the 1980’s, this approach
has been expanded to include the use of cells that have been extensively manipulated in
vitro. For example, autologous keratinocytes were isolated from skin, expanded in vitro and
transplanted to the skin defects of burned patients (Gallico et al., 1984). A similar approach
has been reported for the replacement of damaged cartilage at the knee joint. Cartilage cells
harvested from non-load bearing site of the knee joint were cultured and transplanted to the
damaged site, leading to a significant reduction of pain and increased mobility (Brittberg et
al., 1994). Currently, treatments using living cells (either non-modified or modified cells) are
one of the most promising fields in medicine. As for the field of dentistry, treatments using
living cells have been investigated for several tissues. In particular, bone defects and damaged
salivary glands have been considered as realistic targets for cell-based therapies (Kagami et
al., 1998, 2014; Tran et al., 2011). This chapter will focus on the history and current status of
cell therapy to those dental organs.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Cell therapy to salivary gland
Patients with the irreversible loss of salivary gland function are seen in Sjögren’s syndrome
(SS) and after radiation ± chemotherapy treatment for head and neck cancer. They usually
suffer considerable morbidity and severe reduction in their quality of life because the dys‐
function of the salivary glands leads to severe xerostomia (dry mouth), dysphagia, dental
caries, oro-pharyngeal infections and diminished mucosal wound healing. Although the
etiopathologic bases of SS and radiogenic atrophy are quite different, these conditions arise
from the progressive loss of acinar cells, which are the principal site of fluid-and protein-
secretion in salivary glands. Unfortunately, there are no adequate treatments for patients with
such irreversible glandular damage. Current pharmacological approaches aim to increase the
secretory capacity of the surviving acinar cells but this approach is not feasible if few or no
acinar cells remain in the glands. Therefore, developing alternative treatment strategies to
restore acinar cells in damaged salivary glands are required.
2.1. Experimental approaches to restore the functional salivary glands
Recently, experimental approaches to regenerate functional acinar cells such as the use of gene
therapy, tissue engineering (for developing an artificial gland), or cell-based therapy have been
explored with the aim of developing novel clinical treatments (Baum & Tran, 2006; Baum et
al., 2012; Khalili et al., 2014; Sugito et al., 2004; Sumita et al., 2011; Tran et al., 2005). Gene therapy
involves the transfer of genes into residual cells of atrophied glands to promote saliva secretion,
and it is a promising strategy for a future clinical treatment. This approach focuses on the
delivery of a water-channel protein gene to the surviving ductal epithelial cells using a
recombinant adenovirus vector. In fact, promising results were recently reported from a
clinical trial administering the aquaporin 1 gene for radiogenic dysfunction of salivary glands
(Baum et al., 2012). An alternate strategy, tissue engineering an artificial salivary gland, is also
a promising approach to the replacement of lost or damaged glands. This strategy requires
both salivary epithelial stem/progenitor cells and a biodegradable scaffold that reconstructs
the microenvironment of glandular tissues. We have shown that it is feasible to culture salivary
epithelial cells for their eventual use in a prototype artificial salivary gland (Tran et al., 2005).
However, though this strategy can generate one portion of salivary parenchymal tissue (ductal
cells), it is difficult to regenerate the fully functional salivary tissues (both ductal and acinar
cells). Recently, a fully functional salivary gland in adult mice has been shown possible through
the orthotopic transplantation of a bioengineered salivary gland germ, which was reconsti‐
tuted from epithelial and mesenchymal cells isolated from an embryonic salivary gland germ
(Ogawa et al., 2013). This study provided valuable results for future tissue engineering
strategies to create an artificial salivary gland in patients.
Meanwhile using another experimental strategy, we have focused on a cell-based therapy with
the intention to deliver stem/progenitor cells to atrophic glands by intra-glandular or –venous
injections for increasing the regenerative capacity of the damaged tissues and providing the
salivary gland stem cells that can differentiate to functional acinar cells. To date, promising
cell sources using this strategy have been stem/progenitor cells derived from salivary glands,
New Trends in Tissue Engineering and Regenerative Medicine - Official Book of the Japanese Society for Regenerative
Medicine
82
bone marrow, umbilical cord, or adipose tissue (Khalili et al., 2012, 2014; Kojima et al., 2011;
Lombaert et al., 2008; Sugito et al, 2004; Sumita et al, 2011; Xu et al, 2012). Using cells from the
salivary glands, we previously demonstrated that the cultured rat salivary epithelial cells could
be transplanted into atrophic glands. These cells remained in the damaged gland tissues for 4
weeks (Sugito et al., 2004). Moreover, it was shown that the spheroid culture of adult salivary
gland cells could enrich the progenitor cells (salispheres) and these progenitors restored the
gland morphology and functions after intra-glandular transplantation (Lombaert et al., 2008).
These reports showed that the stem/progenitor cells derived from salivary glands could be
considered as a promising source of cell therapy for the radiogenic dysfunction of salivary
glands. Our group has also focused on bone marrow-derived cells (BMDCs), including
mesenchymal stem cells (MSCs) as a cell-based strategy. We previously found that donor
BMDCs migrated to salivary glands and transdifferentiated into salivary epithelial cells after
their intravenous injection in human patients (Tran et al., 2011). Owing to this, their potential
benefits would have been expected to regenerate the functions of atrophic glands caused by
both SS and radiation therapy. It has been reported that BMDCs display the effects of paracrine,
vasculogenesis, transdifferentiation or immunomodulation after transplantation in the
regeneration of various tissues (Tran et al., 2011). Herein, as a prerequisite for future clinical
trials, we summarize our preliminary results of studies using two different models of damage
to salivary glands, which allowed to analyze the regenerative capacity of BMDCs.
2.2. Behaviors of donor BMDCs in radiogenic dysfunction model
Treatment for most patients with head and neck cancers includes ionizing radiation ± chemo‐
therapy. And, this treatment causes the irreversible damage to salivary glands, which is
accompanied with a loss of fluid-secreting acinar cells and a considerable decrease of saliva
secretion. To develop a cell-based therapy for this dysfunction, we firstly investigated whether
non-cultured fresh BMDCs could differentiate into salivary epithelial cells and restore gland’s
function in head and neck irradiated mice (Sumita et al., 2011). BMDCs from male donor mice
were transplanted through the tail-vein of female recipient mice post gamma-ray irradiation
of 15 or 18 Gy. After 8, 16, and 24 weeks, saliva secretion was increased in mice treated by
BMDCs transplantation (Figure 1).
At 24 weeks after irradiation, harvested submandibular-and parotid-glands of BMDC-treated
mice had greater weights than those of non-treated mice, and possessed an increased level of
tissue regenerative activity (blood vessel formation, cell proliferation, and epidermal growth
factor activity), while apoptosis activity was increased in non-treated salivary glands. The
expression of stem cell markers (Sca-1 or c-Kit) was increased in BMDC-treated salivary glands.
Additionally, we found an increased area of acinar cells and approximately 9% of Y-chromo‐
some positive salivary epithelial cells (derived from the donor) in BMDC-treated mice.
Therefore, we drew a conclusion from this study that cell therapy using BMDCs could rescue
the functional damage of irradiated salivary glands through mechanisms involving a paracrine
effect as well as a direct differentiation of BMDCs into salivary epithelial cells. Likewise, several
studies have shown the beneficial effects of cell-based therapies using MSCs derived from bone
marrow or adipose tissues, to date (Kojima et al., 2011; Lim et al., 2013). In addition, as a proof-
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of-concept of the paracrine effect of (BMDCs) cell-based therapy, our group recently demon‐
strated that the injection of bone marrow cell-extracts (a bioactive lysate of BMDCs) could be
advantageously used to repair the radiogenic dysfunction of salivary glands rather than
BMDCs transplantation (Tran et al., 2013). Although the mechanisms of regeneration are not
well understood at the present, these findings provided a promising result for future clinical
trials of cell-based therapy using BMDCs or MSCs.
2.3. Behaviors of donor BMDCs in SS model
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by infiltrates of
lymphocytes in the salivary glands. In this disease, the immune system attacks the salivary
glands, particularly the acinar cells. This causes an irreversible damage that is accompanied
with a progressive loss of fluid-secreting acinar cells, and leads to a considerable decrease of
saliva secretion. The challenge of successful cell-based therapy for autoimmune diseases is not
only to regenerate the tissue but also to prevent it from the same autoimmune attack that was
responsible for its destruction at the first place (Kodama et al., 2003). Following the above-
mentioned concept, we initially copied a therapy proposed by Faustman and colleagues to
reverse end-stage diabetes in Non-obese diabetic (NOD) mouse, but for the treatment of SS-
like disease (Tran et al., 2007). NOD mice develop SS-like disease and a progressive loss of
saliva secretion. This therapy had two components. First, it was an injection of complete
Freund’s adjuvant (CFA) to induce endogenous TNF-α to exterminate autoreactive T lym‐
phocytes. The second component was the transplantation of MHC class I-matched normal
(Modified from Sumita et al., 2011)
Figure 1. Salivary flow rate recovery after BMDCs transplantation at 8, 16, 24 weeks post-irradiation. SFR were higher
in BMDC-transplanted mice (18Gy+BMDC) when compared to non-transplanted ones (18Gy).
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spleen cells. As a result, our group showed that injections of CFA combined with spleen cells
restored salivary function in NOD mice with SS-like disease (Tran et al., 2007). However for
future clinical consideration, spleen cells are not easily obtained from patients. Therefore our
group modified the Faustman’s two-component therapy by using BMDCs (Khalili et al.,
2010). The spleen and bone marrow are closely related organs, and both are among the first
sites of hematopoiesis during gestation. We injected CFA and MHC class I-matched normal
BMDCs in 7-week-old NOD mice, which had not yet developed SS. At 52 weeks post-
treatment, we found that all NOD mice receiving BMDCs and CFA had a recovery of saliva
secretion and were protected from SS and diabetes. Although a very small number of donor
BMDCs had differentiated into salivary epithelial cells (<0.1%), including acinar cells was
observed, the size of focus score (the number of foci, infiltrated lymphocytes) was bigger in
the non-treated mice (Figure 2).
 
A:  BMDC-t reated NOD             B:  Non-t reated 
NOD   
(Modified from Khalili et al., 2010)
Figure 2. Focus score change after BMDCs transplantation. The size of the focus score (black arrows) was bigger in
non-treated mice (Non-treated NOD) when compared to BMDC-treated mice (BMDC-treated NOD).
This study suggests that a combined immuno and cell-based therapy can permanently prevent
SS and restore the salivary function in NOD mice through mechanisms involving the paracrine
and immunomodulatory effects. Moreover, we analyzed whether this BMDC-treatment would
be effective in restoring salivary gland function if the treatment was given at a late phase of
SS (20-week old NOD) when minimal saliva was secreted. In consequence, saliva secretion
improved and was at best 50 % of pre-symptomatic levels. The treatment also decreased TNF-
α and TGF-β1 levels while increasing EGF and regulatory T cells. This study provided that the
cell-based therapy using BMDCs holds a promising effect, even when given in an advanced
phase of SS. Likewise, we have also confirmed MSCs derived from bone marrow display
similar effectiveness (Khalili et al., 2012). The combined use of CFA and MSCs was effective
in both preventing saliva secretion loss and reducing lymphocytic influx in salivary glands.
Thus, cell-based therapy must be recognized as one of the promising options for future clinical
trials. Recently, our group has also shown that the injection of bone marrow cell extracts (a
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bioactive lysate of BMDCs) could restore the function of damaged salivary gland in NOD mice
(Misuno et al., 2014).
3. Cell-based therapy to atrophic alveolar bone (bone tissue engineering)
Atrophic alveolar bone is one of the major obstacles for dental implant therapy because dental
implant placement requires the presence of a minimal amount of bone. For patients with severe
bone atrophy, functional recovery with conventional dentures is difficult and most of the
patients suffer from masticatory disturbance. A combination of autologous bone graft and
dental implant installation is a realistic option for those patients with severe alveolar bone
atrophy. However, the procedure is accompanied by swelling and pain of the donor site and
causes morbidity. Bioartificial bone substitutes have been frequently used as an alternative,
although the artificial materials cannot induce bone regeneration and the application is limited.
Accordingly, tissue engineering and regenerative medicine of bone tissue is now receiving
significant attention (Kagami et al., 2014).
3.1. Scientific bases for bone tissue engineering
Osteogenic ability is the function to generate bone after transplantation. Before the develop‐
ment of tissue-engineered bone, only vascular bone grafts were known to have this function.
Tissue-engineered bone is designed to contain living osteogenic cells and thus possesses
osteogenic function. The characteristic features of tissue-engineered bone is based on the
presence of osteogenic cells.
As a source for osteogenic cells, pluripotent mesenchymal stromal cells from bone marrow
aspirates have been widely used. Initially, this group of cells was defined as adherent fibro‐
blast-like cells in bone marrow. Since the culture contains cells which can generate single cell-
derived colonies, those cells were referred to as colony forming units-fibroblasts (CFUs-F).
Eventually, CFUs-F were proved to have high proliferating potential and even single-colony
derived cells were shown capable of forming bone (Friedenstein et al., 1966; Friedenstein et al.
1970; Friedenstein et al., 1987). Subsequently, the capability of CFUs-F to differentiate to
various mesenchymal tissues has been reported. Then, these cells were re-named as“mesen‐
chymal stem cells” (MSCs) (Caplan, 1991). However, not all cells are multipotent; MSCs are
also designated as “bone marrow stromal cells (BMSCs)”, which is a relatively widely accepted
nomenclature (Prockop, 2009). Although BMSCs can be obtained from a patient’s own bone
marrow aspirate, the percentage of BMSCs in total bone marrow cells is likely less than 0.01%
(Pittenger et al., 1999). Accordingly, cell cultivation is required to obtain a sufficient number
of cells for clinical bone tissue engineering. For example, bone marrow from a single rat can
provide a sufficient number of osteogenic cells for only two or three bone-forming transplants.
In contrast, after in vitro expansion of cells from the same volume of bone marrow, more than
50 bone-forming transplants are possible (Yoshikawa et al., 1996).
The quality of cells is an important factor for tissue engineering as it could affect the treatment
outcome. Accordingly, BMSCs should be appropriately processed, cultured and induced into
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osteogenic cells. For this purpose, various parameters including cell separation procedures,
culture media, type and origin of serum, cell seeding density, timing of passaging, the number
of passages, content and concentrations of reagents for induction and the period of induction
should be optimized. Similarly, scaffold material and shape should be optimized depending
on the purpose. To establish a standard operating protocol for the preparation of cells for
clinical bone tissue engineering, we have investigated optimal cell culture and induction
procedures using human BMSCs and granular type β-tricalcium phosphate (β-TCP) as a
scaffold. The results showed that the passage number, seeding density and the period of
induction significantly affected the osteogenic ability of BMSCs (Agata et al., 2010). In
particular, human BMSCs lose their in vivo bone forming ability very rapidly after passaging
and no bone formation was observed with cells after the fourth cell passage (Fig. 3) (Agata et
al., 2010). The results of those basic studies should be considered in the establishment of an
optimal cell culture/induction protocol.
Figure 3. Effect of passage numbers on BMSC’s ability for ectopic bone formation. Upper panels show ectopic bone
formation on the back of nude mice with tissue-engineered bone using human BMSCs at passage 1 (a) and passage 5
(b). The success of ectopic bone formation quickly decrease after cell passage and no bone formation was observed
after passage 4 (c). Note that the bone forming ability was quickly lost during passage. Adapted from Kagami et al.,
2014 and modified from original figure in Agata et al., 2010.
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In terms of the safety of bone tissue engineering, BMSCs have been used clinically for more
than ten years and no major side effect has been reported (Quatro et al., 2001). Accordingly,
bone tissue engineering using BMSCs is considered relatively safe. However, genetic instabil‐
ity has been reported in mouse BMSCs, changes that might lead to carcinogenesis (reviewed
by Prockop, 2009). Quest for the usage of more potent stem cells might be accompanied by a
higher risk of genetic alteration, an issue that should be kept in mind in therapeutic applica‐
tions of stem cells.
3.2. Clinical bone tissue engineering in dentistry and maxillofacial surgery
Tissue-engineered bone was first applied for long-bone defects (Quatro et al., 2001). In Quatro’s
study, autologous BMSCs were cultured with hydroxyapatite blocks and transplanted to the
defective site. This study was the first to prove the clinical feasibility of bone tissue engineering.
In the field of dentistry, results from a first clinical study were reported in 2004. MSCs were
mixed with platelet rich plasma as a scaffold and transplanted to the site of atrophic alveolar
bone at the time of dental implant installation (Yamada et al., 2004). They reported that bone
regeneration was observed in all cases. More recently, another clinical study using BMSCs was
reported (Meijer et al., 2008). BMSCs were cultured and seeded on hydroxyapatite granules.
Then, the cells were induced into osteogenic cells for one week and transplanted. In this study,
the subjects included severe atrophy cases in which dental implant could not be installed at
the time of cell transplantation (two steps approach). Bone formation was observed in three
cases. However, in two cases where the atrophy was severe, newly formed bone was only
observed in the area adjacent to the native bone, which might imply osteoconduction rather
than bone regeneration by the transplanted cells. Accordingly, the efficacy of clinical alveolar
bone tissue engineering for severe atrophy cases was not established in this study.
We have conducted a clinical study of bone tissue engineering for severe atrophy of alveolar
bone. BMSCs were harvested from each patient’s bone marrow, expanded in vitro, induced
into osteogenic cells and transplanted together with β-TCP granules (Fig. 4). The results
following two-and five-year observations proved that bone regeneration was successful and
no side effects or related complications have been observed. On the other hand, one of the
important findings through this clinical study was the presence of individual variations in cell
growth, differentiation and levels of bone regeneration (Asahina et al., manuscript in prepa‐
ration). This problem is not limited to bone tissue engineering and might be an important issue
for the all therapies using autologous cells. Development of novel technologies to reduce
individual variation is a current research target.
3.3. Future prospect of bone tissue engineering in dentistry and maxillofacial surgery
Currently, various techniques for bone regeneration/reconstruction are available, including
microvascular-free flaps, autologous block bone transplantation, allogeneic or xenogeneic
bone substitutes or purely artificial bone substitutes. Furthermore, recent development of
additional strategies such as destruction osteogenesis, growth factor administration and tissue
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engineering will provide more options. Accordingly, the selection of an adequate technique
for each case is of importance for practitioners.
When the tissue defect is relatively large and the condition of the recipient site is not optimal,
the use of more invasive technique such as autologous bone grafting might be acceptable.
However, future bone regeneration therapy will probably avoid surgical removal of healthy
bone in favour of less invasive procedures. Bone tissue engineering is one of the most prom‐
ising approaches and is expected to replace cases of autologous bone grafting. Currently, the
best applications and most significant limitations of bone tissue engineering are not clear. Well-
designed clinical studies should be performed to answer these important questions, and these
clinical trials will contribute to the wide acceptance of bone tissue engineering.
4. Conclusion
In the near future, a cell-based therapy will be accepted as a useful or even an essential
treatment option for various diseases in dentistry and maxillofacial surgery. Based on previous
and ongoing studies, radiation-damaged salivary glands and atrophic alveolar bone are the
Figure 4. The procedure for clinical study of alveolar bone regeneration at The Research Hospital, The Institute of
Medical Science, The University of Tokyo. Modified from original figure in Kagami et al., 2014.
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most realistic targets. Despite rapid progress in studies of cell-based therapies, this novel
technology has yet to gain acceptance in ordinary practice. Since cell-based therapy is still
expensive, determination of adequate treatment targets should be an important research goal
to facilitate its widespread use. Furthermore, it is essential to reduce treatment costs without
sacrificing safety. Development of automated cell culture systems and efficient safety tests are
the key technologies to achieve this goal.
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